Pancreatic Cancer Drug Approval: What Oncology Practices Should Update on Their Websites
A safety-first checklist for oncology practices updating their websites after the FDA approval of daraxonrasib.
A treatment approval is a reason to review patient communication
The FDA approval of daraxonrasib for pancreatic cancer gives oncology and cancer-care practices a timely reason to review their treatment-related website content. The approval was reported by The New York Times, while Endpoints placed it in the wider development of KRAS-directed therapies for pancreatic cancer. Read the reporting from The New York Times and Endpoints.
A practice website should not try to determine whether daraxonrasib is appropriate for an individual patient. It should also avoid suggesting that the drug is available through the practice, covered by insurance, or suitable for every person with pancreatic cancer unless the practice has verified those details through appropriate clinical and operational channels.
Instead, use the moment to make the website clearer: publish a sourced update, set safe expectations, explain how patients can contact the right team, and ensure treatment-related messages do not get lost.
Table of contents
- Start with a careful, factual announcement
- State what the website cannot determine
- Create a safe path for patient questions
- Review forms, routing, and after-hours messaging
- Avoid common website mistakes after a drug approval
- A practical publication checklist
- A short website-service bridge
Start with a careful, factual announcement
A short news post or treatment-update page can acknowledge the FDA approval without turning the practice website into a treatment guide.
Keep the announcement limited to facts supported by your sources. For example:
The FDA has approved daraxonrasib for pancreatic cancer. Treatment decisions, including whether a particular therapy may be relevant, require evaluation by a qualified oncology team. Patients with questions should contact their care team or request an appointment through the appropriate practice channel.
Before publishing, have an appropriate clinical reviewer confirm every statement about the approval and the practice’s own processes.
Link to the source material
A page about a major approval should identify where the information came from. Link to reputable reporting or to the relevant official material your clinical team has approved for publication. In this case, the reported approval is covered by The New York Times and Endpoints.
A source link helps distinguish a timely practice update from unsupported marketing copy.
Give the page a specific date
Use a visible publication or review date, such as “Reviewed August 2026,” if that date has been confirmed by your practice. Timely oncology news can change quickly, and a dated page gives patients and caregivers useful context.
Do not leave an old announcement live indefinitely without reviewing whether the language, links, and contact instructions remain accurate.
State what the website cannot determine
Patients and caregivers may search for a new treatment approval while facing difficult, time-sensitive decisions. Clear limits are not a legal disclaimer buried at the bottom of a page; they are part of safe communication.
Your page should say plainly that online information cannot confirm:
- Whether daraxonrasib is appropriate for a particular patient
- Whether a patient meets any treatment criteria
- Whether the practice offers or can prescribe the treatment
- Whether the treatment is currently available to that patient
- Whether insurance will cover treatment
- What a patient’s individual outcome may be
Those questions require evaluation by the patient’s oncology team and the practice’s established clinical, scheduling, and financial-support processes.
Do not imply universal eligibility or expected results
Avoid headlines and calls to action such as:
- “A new option for every pancreatic cancer patient”
- “Find out if this drug will work for you”
- “Get access to the latest pancreatic cancer treatment”
- “FDA-approved treatment now available here”
Even if a phrase seems well-intentioned, it can overstate what the practice can determine online or what the approval means for an individual.
A more responsible headline is: “FDA approval of daraxonrasib: information for patients and caregivers.” The copy beneath it can direct visitors to their oncology team for individualized guidance.
Create a safe path for patient questions
An announcement matters only if a visitor can tell what to do next. The right next step will differ for current patients, referring clinicians, and people seeking an initial consultation.
Separate current-patient and new-patient instructions
Current patients may need to contact their established care team through the practice’s normal patient-communication channel. New patients may need to request a consultation through a dedicated intake form or scheduling line.
Make that distinction visible on the page. A simple two-path layout can prevent a current patient from submitting a general inquiry when they should use their normal care channel.
For current patients: “Please contact your established oncology care team through the practice’s usual patient communication channel.”
For people seeking a consultation: “To request an appointment, use the consultation request form or contact our scheduling team.”
Only publish contact methods that your practice actively monitors and has approved for that purpose.
Put urgent-care guidance before the form
Do not let a general website form appear to be an urgent-care channel. Near the contact options, direct visitors with urgent concerns to the practice’s published urgent-care instructions or to emergency care where appropriate.
Keep this message clear and visually close to the form. Do not rely on a footer disclaimer.
Explain what patients should not send through a general form
A website inquiry form is not the right place for detailed medical histories, test results, or urgent clinical questions. Use plain language to explain that the form is for appointment or general practice inquiries and that individualized treatment decisions require the oncology team.
For a wider review of what a public-facing form should collect and disclose, see Local Business Website Lead Form Privacy Checklist.
Review forms, routing, and after-hours messaging
Neither reported source shows that oncology practices have received more inquiries following this approval. Still, practices should prepare for the possibility that patients and caregivers may ask about the drug, eligibility, availability, or appointments.
The practical risk is not simply receiving more messages. It is receiving treatment-related questions through a form that routes to the wrong person, has unclear expectations, or is not monitored when visitors assume it is.
Add a simple inquiry category
If your practice uses a consultation or contact form, consider adding a limited category selector such as:
- Appointment request
- Treatment-related question
- Referral inquiry
- General practice question
Do not use the form to collect detailed clinical information unless your practice has established and approved that process. The goal is routing—not online triage.
A selected “treatment-related question” category can help direct the message to the appropriate scheduling, intake, or clinical workflow without asking a visitor to diagnose themselves.
Confirm who receives each form submission
Test the actual workflow, not just the form design:
- Submit a test inquiry.
- Confirm the notification reaches the intended inbox or system.
- Check that the message identifies the inquiry category.
- Verify that a staff member or team owns the next step.
- Confirm the sender sees an accurate acknowledgment message.
- Review whether after-hours submissions are handled according to the practice’s published process.
For more on preventing missed inquiries, read Local Business Website Lead Notifications: How to Stop Missing New Inquiries and How Local Businesses Should Handle Website Leads That Arrive After Hours.
Update the confirmation message
The thank-you page and automated acknowledgment should set expectations without making clinical promises.
A suitable confirmation might say:
We received your inquiry. This form is not monitored for urgent medical concerns and cannot provide individualized treatment guidance. Our team will follow the practice’s established process for appointment and general inquiries.
Do not promise a response time unless the practice can reliably meet it. Do not imply that submitting the form creates a patient relationship, confirms eligibility, or reserves treatment.
For more confirmation-page basics, see What to Put on a Local Business Website Thank-You Page After a Form Submission.
Avoid common website mistakes after a drug approval
Publishing a page before clinical review
A fast update is not helpful if it contains unsupported details about indications, outcomes, availability, or coverage. Establish who approves treatment-related website language before the page goes live.
Treating news reporting as a clinical FAQ
News articles can support a factual announcement, but they do not replace clinical guidance for individual patients. Keep the page focused on the reported approval and the practice’s communication path.
Making availability claims without verification
Do not say “now offered,” “available at our center,” or similar language unless the practice has confirmed that statement and has a process for keeping it current.
Sending every question to one generic inbox
A general inbox may be appropriate for some practices, but treatment-related inquiries can require different routing than media, billing, referral, or routine contact questions. Make ownership explicit.
Hiding contact instructions on a crowded service page
A visitor reading about a newly approved drug should not need to search the navigation to find the right next step. Use a visible, concise contact block on the announcement page itself.
A clear contact page also helps visitors choose an appropriate channel. See 7 Contact Page Mistakes That Cost Local Businesses Leads.
A practical publication checklist
Before publishing or revising a daraxonrasib-related website update, confirm the following.
Content checks
- The approval announcement is supported by reputable, reviewed sources.
- The page does not claim cure rates, outcomes, universal eligibility, insurance coverage, or local availability without verified support.
- The page states that treatment decisions require a qualified oncology team.
- The update has a visible publication or review date.
- The practice has approved the language through its appropriate review process.
Patient-communication checks
- Current patients can identify their normal care-team contact path.
- New patients can identify the consultation or appointment path.
- Urgent concerns are directed to the practice’s published urgent-care instructions or emergency care where appropriate.
- The page does not present a general web form as an urgent-care channel.
- The form explains its intended use and avoids inviting detailed medical information through an unsuitable channel.
Operations checks
- Treatment-related inquiries have a defined owner or routing path.
- Form notifications have been tested.
- The acknowledgment message sets accurate expectations.
- After-hours messaging matches the practice’s actual process.
- The page is scheduled for future review as treatment information and practice operations change.
A short website-service bridge
For oncology practices, a treatment-related announcement should be accurate, readable on a phone, and connected to a contact workflow the practice can actually manage. StoopCraft builds websites for local businesses and includes on-page SEO as part of its $69/month service. If your practice needs help maintaining clear website pages and contact paths, visit StoopCraft.
